43 related articles for article (PubMed ID: 17924589)
1. The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.
Shilbayeh SAR; Adeen IS; Alhazmi AS; Aljurayb H; Altokhais RS; Alhowaish N; Aldilaijan KE; Kamal M; Alnakhli AM
Eur J Clin Pharmacol; 2024 Jun; 80(6):869-890. PubMed ID: 38421437
[TBL] [Abstract][Full Text] [Related]
2. Associations of Genetic Polymorphisms and Neuroimmune Markers With Some Parameters of Frontal Lobe Dysfunction in Schizophrenia.
Morozova A; Zorkina Y; Pavlov K; Pavlova O; Abramova O; Ushakova V; Mudrak AV; Zozulya S; Otman I; Sarmanova Z; Klyushnik T; Reznik A; Kostyuk G; Chekhonin V
Front Psychiatry; 2021; 12():655178. PubMed ID: 34025476
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation.
van Noord C; Aarnoudse AJ; Eijgelsheim M; Sturkenboom MC; Straus SM; Hofman A; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
Pharmacogenet Genomics; 2009 Apr; 19(4):260-6. PubMed ID: 19247217
[TBL] [Abstract][Full Text] [Related]
4. Association between the rs6313 polymorphism in the 5-HTR2A gene and the efficacy of antipsychotic drugs.
Wang Y; Tan X; Chen Z; Zhang B; Gao Y; Wang Y
BMC Psychiatry; 2023 Sep; 23(1):682. PubMed ID: 37726709
[TBL] [Abstract][Full Text] [Related]
5. Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine.
De Pieri M; Ferrari M; Marino F; Traber R; Bolla E; Cosentino M
Front Pharmacol; 2023; 14():1182393. PubMed ID: 37229261
[TBL] [Abstract][Full Text] [Related]
6. Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.
Shad MU
Behav Sci (Basel); 2021 Jun; 11(7):. PubMed ID: 34209185
[TBL] [Abstract][Full Text] [Related]
7. Use of combinatorial pharmacogenomic testing in two cases from community psychiatry.
Fields ES; Lorenz RA; Winner JG
Pharmgenomics Pers Med; 2016; 9():79-84. PubMed ID: 27574460
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of antipsychotics.
Brandl EJ; Kennedy JL; Müller DJ
Can J Psychiatry; 2014 Feb; 59(2):76-88. PubMed ID: 24881126
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.
Reynolds GP; McGowan OO; Dalton CF
Br J Clin Pharmacol; 2014 Apr; 77(4):654-72. PubMed ID: 24354796
[TBL] [Abstract][Full Text] [Related]
10. The potential role of dopamine D₃ receptor neurotransmission in cognition.
Nakajima S; Gerretsen P; Takeuchi H; Caravaggio F; Chow T; Le Foll B; Mulsant B; Pollock B; Graff-Guerrero A
Eur Neuropsychopharmacol; 2013 Aug; 23(8):799-813. PubMed ID: 23791072
[TBL] [Abstract][Full Text] [Related]
11. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.
Almoguera B; Riveiro-Alvarez R; Lopez-Castroman J; Dorado P; Vaquero-Lorenzo C; Fernandez-Piqueras J; Llerena A; Abad-Santos F; Baca-García E; Dal-Ré R; Ayuso C;
Pharmacogenomics J; 2013 Apr; 13(2):197-204. PubMed ID: 22212732
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of response to antipsychotics in patients with schizophrenia.
Arranz MJ; Rivera M; Munro JC
CNS Drugs; 2011 Nov; 25(11):933-69. PubMed ID: 22054119
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Singh SP; Singh V
CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
Zhang JP; Malhotra AK
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):9-37. PubMed ID: 21162693
[TBL] [Abstract][Full Text] [Related]
15. Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.
Archer T; Kostrzewa RM; Palomo T; Beninger RJ
Neurotox Res; 2010 Nov; 18(3-4):211-28. PubMed ID: 20237882
[TBL] [Abstract][Full Text] [Related]
16. The promise and reality of pharmacogenetics in psychiatry.
Zandi PP; Judy JT
Psychiatr Clin North Am; 2010 Mar; 33(1):181-224. PubMed ID: 20159346
[TBL] [Abstract][Full Text] [Related]
17. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.
Chen SF; Shen YC; Chen CH
Psychopharmacology (Berl); 2009 Aug; 205(2):285-92. PubMed ID: 19387614
[TBL] [Abstract][Full Text] [Related]
18. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
Kim B; Choi EY; Kim CY; Song K; Joo YH
Hum Psychopharmacol; 2008 Jan; 23(1):61-7. PubMed ID: 17924589
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.
Al Hadithy AF; Ivanova SA; Pechlivanoglou P; Semke A; Fedorenko O; Kornetova E; Ryadovaya L; Brouwers JR; Wilffert B; Bruggeman R; Loonen AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):475-81. PubMed ID: 19439249
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
